{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 398756829
| IUPAC_name = (3''S'',4a''R'',6''R'',8a''R'')-6-[2-(1''H''-tetrazol-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid
| image = Tezampanel.svg
| width = 250

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- Schedule I -->
| legal_UK = <!-- Class A -->
| legal_US =  
| legal_status = Investigational
| routes_of_administration = [[Intravenous therapy|IV]]

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 4245
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 150131-78-5
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 127894
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = GA36S2O9C2
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 113428
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 14935
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D06656

<!--Chemical data-->
| C=13 | H=21 | N=5 | O=2 
| molecular_weight = 279.338 g/mol
| smiles = C1C[C@H]2CN[C@@H](C[C@H]2C[C@H]1CCC3=NNN=N3)C(=O)O
| synonyms =  
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C13H21N5O2/c19-13(20)11-6-10-5-8(1-3-9(10)7-14-11)2-4-12-15-17-18-16-12/h8-11,14H,1-7H2,(H,19,20)(H,15,16,17,18)/t8-,9+,10-,11+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = ZXFRFPSZAKNPQQ-YTWAJWBKSA-N
}}

'''Tezampanel''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) (code names '''LY-293,558''', '''NGX-424''') is a [[drug]] originally developed by [[Eli Lilly and Company|Eli Lilly]]<ref>Gilron I. LY-293558. Eli Lilly & Co. ''Current Opinion in Investigational Drugs''. 2001 Sep;2(9):1273-8. {{PMID|11717815}}</ref> which acts as a [[competitive antagonist]] of the [[AMPA receptor|AMPA]] and [[kainate receptor|kainate subtype]]s of the [[ionotropic glutamate receptor]] family,<ref>Ornstein PL, Arnold MB, Augenstein NK, Lodge D, Leander JD, Schoepp DD. (3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist. ''Journal of Medicinal Chemistry''. 1993 Jul 9;36(14):2046-8. {{PMID|8393116}}</ref><ref>Schoepp DD, Lodge D, Bleakman D, Leander JD, Tizzano JP, Wright RA, Palmer AJ, Salhoff CR, Ornstein PL. In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid. ''Neuropharmacology.'' 1995 Sep;34(9):1159-68. {{PMID|8532186}}</ref> with selectivity for the [[GluR5]] subtype of the kainate receptor.<ref>Bleakman R, Schoepp DD, Ballyk B, Bufton H, Sharpe EF, Thomas K, Ornstein PL, Kamboj RK. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid. ''Molecular Pharmacology''. 1996 Apr;49(4):581-5. {{PMID|8609884}}</ref><ref>Li H, Rogawski MA. GluR5 kainate receptor mediated synaptic transmission in rat basolateral amygdala in vitro. ''Neuropharmacology.'' 1998Oct-Nov;37(10-11):1279-86. PubMed {{PMID|9849665}}.</ref> It has [[neuroprotective]]<ref>Bullock R, Graham DI, Swanson S, McCulloch J. Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat. ''Journal of Cerebral Blood Flow and Metabolism''. 1994 May;14(3):466-71. {{PMID|8163588}}</ref> and [[anticonvulsant]] properties,<ref>Rogawski MA, Kurzman PS, Yamaguchi SI, Li H. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. ''Neuropharmacology.'' 2001;40(1):28-35. PubMed {{PMID|11077068}}.</ref> the former of which may, at least in part, occur via blockade of [[calcium]] [[Neurotransmitter transporter|uptake]] into [[neuron]]s.<ref>Liljequist S, Cebers G, Kalda A. Effects of decahydroisoquinoline-3-carboxylic acid monohydrate, a novel AMPA receptor antagonist, on glutamate-induced CA2+ responses and neurotoxicity in rat cortical and cerebellar granule neurons. ''[[Biochemical Pharmacology (journal)|Biochemical Pharmacology]]''. 1995 Nov 27;50(11):1761-74. {{PMID|8615854}}</ref>

Tezampanel has a range of effects which may be useful for [[medicine|medicinal purpose]]s, as well as its applications in [[scientific research]]. It suppresses both the [[drug withdrawal|withdrawal]] [[symptom]]s from [[morphine]] and other [[opioid]]s,<ref>Rasmussen K, Kendrick WT, Kogan JH, Aghajanian GK. A selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. ''Neuropsychopharmacology''. 1996 Nov;15(5):497-505. {{PMID|8914123}}</ref><ref>Kest B, McLemore G, Kao B, Inturrisi CE. The competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist LY293558 attenuates and reverses analgesic tolerance to morphine but not to delta or kappa opioids. ''Journal of Pharmacology and Experimental Therapeutics''. 1997 Dec;283(3):1249-55. {{PMID|9400000}}</ref><ref>McLemore GL, Kest B, Inturrisi CE. The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence. ''Brain Research''. 1997 Dec 5;778(1):120-6. {{PMID|9462883}}</ref> and the development of [[tachyphylaxis|tolerance]],<ref>Carlezon WA Jr, Rasmussen K, Nestler EJ. AMPA antagonist LY293558 blocks the development, without blocking the expression, of behavioral sensitization to morphine. ''Synapse''. 1999 Mar 15;31(4):256-62. {{PMID|10051106}}</ref> as well as having [[Hyperalgesia|antihyperalgesic]]<ref>Sang CN, Hostetter MP, Gracely RH, Chappell AS, Schoepp DD, Lee G, Whitcup S, Caruso R, Max MB. AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. ''Anesthesiology''. 1998 Nov;89(5):1060-7. {{PMID|9821993}}</ref> and [[analgesic]] effects in its own right.<ref>Gilron I, Max MB, Lee G, Booher SL, Sang CN, Chappell AS, Dionne RA. Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. ''Clinical Pharmacology and Therapeutics''. 2000 Sep;68(3):320-7. {{PMID|11014414}}</ref><ref>Von Bergen NH, Subieta A, Brennan TJ. Effect of intrathecal non-NMDA EAA receptor antagonist LY293558 in rats: a new class of drugs for spinal anesthesia. ''Anesthesiology''. 2002 Jul;97(1):177-82. {{PMID|12131120}}</ref><ref>Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, Silberstein SD, Johnson KW, Phebus LA, Bleakman D, Ornstein PL, Arnold B, Tepper SJ, Vandenhende F. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. ''Cephalalgia''. 2004 Jul;24(7):596-602. {{PMID|15196302}}</ref><ref>Lee HJ, Pogatzki-Zahn EM, Brennan TJ. The effect of the AMPA/kainate receptor antagonist LY293558 in a rat model of postoperative pain. ''Journal of Pain''. 2006 Oct;7(10):768-77. {{PMID|17018337}}</ref><ref>Jin HC, Keller AJ, Jung JK, Subieta A, Brennan TJ. Epidural tezampanel, an AMPA/kainate receptor antagonist, produces postoperative analgesia in rats. ''Anesthesia and Analgesia''. 2007 Oct;105(4):1152-9. {{PMID|17898404}}</ref> It also has [[anxiolytic]] effects in [[animal model|animal studies]] and has been suggested as a candidate for the treatment of [[anxiety]] in humans.<ref>Alt A, Weiss B, Ogden AM, Li X, Gleason SD, Calligaro DO, Bleakman D, Witkin JM. In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders. ''Psychopharmacology''. 2006 Apr;185(2):240-7. {{PMID|16470401}}</ref>

==References==
{{Reflist|2}}

{{Ionotropic glutamate receptor modulators}}

[[Category:AMPA receptor antagonists]]
[[Category:Analgesics]]
[[Category:Anticonvulsants]]
[[Category:Antimigraine drugs]]
[[Category:Carboxylic acids]]
[[Category:Decahydroisoquinolines]]
[[Category:Eli Lilly and Company]]
[[Category:Kainate receptor antagonists]]
[[Category:Neuroprotective agents]]
[[Category:Tetrazoles]]